CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
Mavacamtendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05414175
NCT05414175Phase 3Completed
CompareCT.gov

A Phase 3, Open-label, Single Arm, Clinical Study to Evaluate Efficacy, Safety and Tolerability of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol-Myers Squibb·interventional·Posted Jun 10, 2022·Updated Jan 27, 2026

In Brief

A Phase 3 clinical trial evaluating Mavacamten for Cardiomyopathy, Hypertrophic Obstructive. Completed, enrolled 38 participants across 20 sites.

Detailed Summary

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiomyopathy, Hypertrophic Obstructive
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedJun 10, 2022
Enrollment StartAug 19, 2022
Primary CompletionNov 27, 2023
Study CompletionDec 11, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.1 years ago

Interventions

Mavacamtendrug

Specified dose on specified days